🧠 Food for thought

Implications, context, and why it matters.

Regulatory validation unclear despite ‘medically reviewed’ marketing claim

• Sol markets its app as ‘medically reviewed’ and ‘evidence-based’ 1. It gives no details on regulatory classification with Singapore’s Health Sciences Authority (HSA) or Hong Kong’s Department of Health, clinical validation, or published outcomes.
• The gap matters since only 7% of physicians-in-training feel prepared 2, while many supplements lack proven effectiveness or safety 3.
• Its proprietary ‘3-level scorecard’ for treatment choice lacks peer-reviewed validation or comparisons to clinical guidelines, so accuracy stays unknown 1. Corporate IT (information technology) and procurement often seek ISO 13485 (a quality-management standard for medical devices) or measured outcomes before approving employee health tools. Past opacity in supplement ingredients, plus side effects, adds to that bar 3.

HR tech vendors can capture APAC menopause benefits market before category matures

• Employee benefits platforms and EAP (Employee Assistance Program) providers in Asia have a near-term B2B (business-to-business) opening. In Singapore, 74% of women aged 45+ say symptoms hurt job ability, yet only 31% of companies have policies while 71% of female employees want them 4.
• Early entrants can gain ground as care stays fragmented. The US counts an estimated 55 million women in menopause, yet only about 1,300 Menopause Society Certified Practitioners (a clinical credential for clinicians specializing in menopause care) serve worldwide, roughly one specialist per 42,000 women 2.
• Insurers with telehealth vendors (remote care delivered via digital channels) should partner with large employers in Singapore where symptoms disrupt work. Over half of affected women hold middle to senior leadership roles 4. Standard Chartered, HSBC Singapore, S&P Global offer menopause medical coverage. Flexible arrangements join those benefits, which signals demand 4.